ProSavin
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (February 2009) |
ProSavin is an experimental drug believed to be of use in the treatment of Parkinson's Disease. It is administered to the striatum in the brain, inducing production of dopamine.[1]
It is manufactured by Oxford BioMedica, who plan to start European Phase I and Phase II clinical trials in 2007. Animal trials have been a success, with dopamine levels restored without the side effects associated with other current treatments for Parkinson's,[2] in particular, without the jerky involuntary movements associated with current drugs.[3]
Mechanism of Action
Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase, tyrosine hydroxylase and GTP-cyclohydrolase 1, to the striatum in the brain, reprogramming transduced cells to secrete dopamine.[4]
See also
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- ↑ Oxford BioMedica. Drug Information Page. Retrieved on March 29, 2007.
- ↑ Daily Telegraph. Investor Information. Retrieved on March 29, 2007.
- ↑ Ben Hirschler (2009-10-14). "Long-term monkey tests back Oxford's gene therapy". Reuters. Retrieved 2009-10-14.
- ↑ Oxford BioMedica . Drug Advanced Information Page. Retrieved on April 5, 2007.
